Influence of long-term low molecular weight heparin nebulization on clinical parameters and the course of allergic inflammation in patients with asthma;Wpływ heparyny niskocza̧steczkowej w przewlekłej nebulizacji na wybrane parametry kliniczne i przebieg zapalenia alergicznego u pacjentów z astma̧ oskrzelowa̧

Polskie Archiwum Medycyny Wewnetrznej

Volumn 106, Issue 6, 2001, Pages 1121-1129

  Fal, Andrzej M ^a   Miecielica, Jadwiga ^a   Krasnowska, Maryla ^a   Mȩdrala, Wojciech ^a   Kuryszko, Jan ^b   Malolepszy, Józef ^a  

^a Kat i Klinika Chorob W   (Poland)

^b Akademii Rolniczej we W

Author keywords

Asthma; ECP; FEV1; Low molecular weight heparin; Treatment

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 5; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; SCLEROPROTEIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ALLERGY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHOSCOPY; BRONCHUS BIOPSY; BRONCHUS MUCOSA; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; EOSINOPHIL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LONG TERM CARE; LUNG LAVAGE; MACROPHAGE; MALE; NEBULIZATION; NEUTROPHIL; PROTEIN EXPRESSION; SPIROMETRY; BIOPSY; BRONCHITIS; BRONCHUS; CLINICAL TRIAL; CYTOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MIDDLE AGED; NEBULIZER; PATHOLOGY;

ADMINISTRATION, INHALATION; ADULT; ASTHMA; BIOPSY; BRONCHI; BRONCHITIS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; RESPIRATORY FUNCTION TESTS;

EID: 2242446107     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Malolepszy J., Fal A.M.: Ocena parametrów zapalenia alergicznego w popłuczynach oskrzelowych chorych na astmȩ. Evaluation of allergic inflammation parameters in bronchoalveolar lavage in patients with asthma. Pneumonol. Alergol. Pol., 1995, 63, 484-89.
2. Barbato A., Panizzolo C., Gheno M. i wsp.: Bronchoalveolor lavage in asthmatic children: evidence of neutrophil activation in mild-to moderate persistent asthma. Pediatr. Allergy Immunol., 2001, Apr. 12(2), 73-7.
3. Gibson P.G., Simpson J.L., Saltos N.: Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001 May, 119(5), 1329-36.
4. Nocker R.E., Out T.A., Weller F.R. i wsp.: Influx of neutrophils into the airway lumen at 4 h after segmental allergen challenge in asthma. Int. Arch. Allergy Immunol. 1999, May, 119(1), 45-53.
5. Matsumoto H., Niimi A., Minakuchi M., Izumi T.: Serum eosinophil cationic protein levels measured during exacerbation of asthma: characteristics of patients with low titres. Clin. Exp. Allergy 2001 Apr. 31 (4), 637-43.
6. Zimmerman B., Lanner A., Enander I. i wsp.: Total blood eosinophils serum eosinophil cationic protein and eosinophil protein X in childhood asthma: Relation to disease status and therapy. Clin. Exp. Allergy, 1993, 23, 564-570.
7. Ahmed T., Syriste T., Mendelssohn R. i wsp.: Heparin prevents antigen-induced airway hyperresponsiveness. Interference with IP-3-mediated mast cell degranulation? J. Appl. Physiol., 1994, 76(2), 893.
8. Ahmed T., Garrigon J., Danta J.: Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N. Engl. J. Med., 1993, 329, 90.
9. Ahmed T., Gonzalez B.J., Danta I.: Prevention of exercise-induced bronchocostricion by inhaled low-molecular-weight heparin. Am. J. Respir. Crit. Care Med., 1999, 160, 576.
10. Bowler S.D., Smith S.M., Lavercombe P.S.: Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am. Rev. Respir. Dis., 1993, 147, 160.
11. Antczak M., Kuna P.: Heparin inhibits allergen induced airway response in asthmatics. Results of a double-blind, placebo controlled, crossover study. J. Allergol. Clin. Immunol., 1995, 951 (Part. 2), 386.
12. Kuna P., Antczak M.: The effect of inhaled heparin on allergen induced bronchial hyperresponsiveness in asthmatic patients. Allergy, 1995, 50 (suppl. 26), 25.
13. Montefort S., Roche W.R., Howarth P.H. i wsp.: Intercellular adhesion molecule-1 expression in the bronchial mucosa of normal and asthmatic subjects. Eur. Respir. J., 1992, 5, 815.
14. Kyun Aung V., Haskard D.O., Poston R.N., Thornhill M.H., Lee T.H.: Endothelial leucocyte adhesion molecule-1 and intercellular adhesion molecule-1 mediate the adhesion of eosinophils to endothelial cells in vitro and are expressed by endothelium in allergic cutaneous inflammation in vivo. J. Immunol., 1991, 146, 521.
15. Zangrilli J.G., Shaver I.R., Cirelli R.A. i wsp.: sVCAM-1 levels after segmental antigen challenge correlate with eosinophil influx, IL-4 and IL-5 production, and the late phase response. Am. J. Respir. Crit. Care Med., 1995, 151,(5), 1346.
16. Petrov D., Tsevtkov O., Gurcher R. i wsp.: Inhalation treatment with low doses of heparin in bronchial asthma patients. Wnutr. Bolest., 1987, 26, 98.
17. Barbato A., Panizzolo G., Gheno M. i wsp.: Bronchoalveolar lavage in asthmatic children: evidence of neutrophil activation in mild-to-moderate persistent asthma. Pediatr. Allergy Immunol., 2001, 12(2), 73.
18. Gibson P.G., Simpson J.L., Saltos N.: Heterogeneity of airway inflammation in persitent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001 May, 119(5), 1329.
19. Nocker R.E., Out T.A., Weller F.R. i wsp.: Influx of neutrophils into the airway lumen at 4 h after segmental allergen challenge in asthma. Int. Arch. Allergy Immunol., 1999 May, 119(1), 45.
20. Barker R.L., Grundel R.H., Gleich G.J. i wsp.: Acidic polyaminoacids inhibit eosinophil granule major basic protein toxicity. J. Clin. Invest., 1991, 88, 798.
21. Trocme S.D., Hallberg C.K.: Heparin and hyaluronate prevent major basic protein inhibition of corneal epithelial healing. Progress in Allergy and Clinical Immunology, 1997, 386.
22. Koizumi A., Hashimoto S., Kobayashi T., Imai K., Yachi A., Horie T.: Elevation of serum soluble vascular cell adhesion molecule-1 (sVCAM-1) levels in bronchial asthma. Clin. Exp. Immunol., 1995, 101(3), 468.
23. Sim T.C., Kunimoto M., Reece I., Patel J.A.: Effect of heparin on cytokine produktion by respiratory syncytial virus (RSV)-infected human airway epithelial cells. J. Allergy Clin. Immunol., 1995, 95, 389.
24. Takatsu K., Ogata N.: Cytokines and receptors regulating allergy. Progress in Allergy and Clinical Immunology, 1997, 85.
25. Lacoste J.Y., Bousquet J., Chanez P. i wsp.: Eosinophilic et neutrophilic inflammation in asthma, chronic bronchitis and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol., 1993, 92, 537.
26. Walker C., Kaegi M.K., Braun P., Blaser K.: Activated T cells and eosinophils in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J. Allergy Clin. Immunol., 1991, 88, 935.
27. Antczak-Marczak M., Kuna P.: Wpływ heparyny na chemotaksjȩ eozynofilów wywołana̧ chemokina̧ RANTES i FMLP. Pneumonal. Alergol. Pol., 1997, 65, 588.
28. Antczak-Marczak M., Kuna P.: Wpływ heparyny na uwalnianie histaminy z bazofilów pod wpływem MCAF/MCP-1 u chorych na astmȩ oskrzelowa̧. Pneumonol. Alergol. Pol., 1997, 65, 581.
29. Jankowska B.: Wpływ heparyny na ekspresjȩ endoteliny w płucach szezurów z przewlekłym zapaleniem oskrzeli wywołanym dwutlenkiem siarki. Rozprawa Doktorska. AM Wrocław, 1999.
30. Juntumen-Backamn K., Järvinen P., Sorva R.: Serum eosinophil cationic protein during treatment of asthma in children. J. Allergy Clin. Immunol., 1993, 92, 34.
31. Matsumoto H., Niimi A., Minakuchi M., Izumi T.: Serum eosinophil cationic protein levels measured during exacerbation of asthma: characteristics of patients with low titres. Clin. Exp. Allergy, 2001, (4), 637.
32. Zimmerman B., Lanner A., Enander I. i wsp.: Total blood eosinophils serum eosinophil cationic protein and eosinophil protein X in childhood asthma: Relation to disease status and therapy. Clin. Exp. Allergy, 1993, 23, 564.